Are CSF CXCL13 concentrations solely dependent on intrathecal production? A commentary on “Chemokine CXCL13 in serum, CSF, and blood–CSF barrier function”
Tóm tắt
Pilz et al. (Fluids Barriers CNS 17:7; 2020) investigated how CSF CXCL13 concentrations are influenced by CXCL13 serum concentrations and blood-CSF barrier (BCSFB) function, comparing the impact of serum CXCL13 levels and Qalbumin (CSF albumin/serum albumin) on CSF CXCL13 among patients with CNS inflammation categorized as CXCL13 negative, low, medium, or high. Among all CXCL13 groups, their results showed no correlation between CSF CXCL13 concentrations and serum CXCL13 or Qalbumin. The authors argue that, in contrast to other proteins, CXCL13 passage across the BCSFB does not occur, regardless of BCSFB function, and is instead solely influenced by intrathecal production. In contrast to the authors’ findings, in our studies including both non-inflammatory neurological disorders (NIND; n = 62) and multiple sclerosis (MS) patients we observed a significant correlation between serum CXCL13 concentrations and CSF CXCL13 concentrations. We review several observations which may underlie these contrasting results, including (1) the impact of serum CXCL13 concentrations on CSF CXCL13 in patients with lower intrathecal CXCL13 production and thus lower CXCL13 concentrations (i.e. NIND and MS), (2) the proposed diffusion dynamics of the small molecule CXCL13 across the BCSFB, and (3) differing definitions of negative versus elevated CSF CXCL13 concentrations determined by an assay’s relative sensitivity. In conclusion, we argue that for patients with moderately elevated CSF CXCL13 concentrations, serum CXCL13 concentrations influence CSF CXCL13 levels, and thus the appropriate corrections including incorporation of CSF/serum ratios and Qalbumin values should be utilized.
Tài liệu tham khảo
Sellebjerg F, Bornsen L, Khademi M, et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology. 2009;73:2003–10. https://doi.org/10.1212/WNL.0b013e3181c5b457.
Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol. 2012;30:429–57. https://doi.org/10.1146/annurev-immunol-020711-075032.
Havenar-Daughton C, Lindqvist M, Heit A, et al. CXCL13 is a plasma biomarker of germinal center activity. Proc Natl Acad Sci U S A. 2016;113:2702–7. https://doi.org/10.1073/pnas.1520112113.
Lalor SJ, Segal BM. Lymphoid chemokines in the CNS. J Neuroimmunol. 2010;224:56–61. https://doi.org/10.1016/j.jneuroim.2010.05.017.
Phares TW, DiSano KD, Stohlman SA, et al. CXCL13 promotes isotype-switched B cell accumulation to the central nervous system during viral encephalomyelitis. Brain Behav Immun. 2016;54:128–39. https://doi.org/10.1016/j.bbi.2016.01.016.
Pilz G, Sakic I, Wipfler P, et al. Chemokine CXCL13 in serum, CSF and blood-CSF barrier function: evidence of compartment restriction. Fluids Barriers CNS. 2020;17:7. https://doi.org/10.1186/s12987-020-0170-5.
Reiber H. Flow rate of cerebrospinal fluid (CSF)–a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J Neurol Sci. 1994;122:189–203. https://doi.org/10.1016/0022-510x(94)90298-4.
Regeniter A, Kuhle J, Mehling M, et al. A modern approach to CSF analysis: pathophysiology, clinical application, proof of concept and laboratory reporting. Clin Neurol Neurosurg. 2009;111:313–8. https://doi.org/10.1016/j.clineuro.2008.12.004.
Reiber H. Cerebrospinal fluid–physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Multiple sclerosis (Houndmills, Basingstoke, England). 1998;4:99–107.
Pachner AR, Dail D, Narayan K, et al. Increased expression of B-lymphocyte chemoattractant, but not pro-inflammatory cytokines, in muscle tissue in rhesus chronic Lyme borreliosis. Cytokine. 2002;19:297–307.
Narayan K, Dail D, Li L, et al. The nervous system as ectopic germinal center: CXCL13 and IgG in lyme neuroborreliosis. Ann Neurol. 2005;57:813–23. https://doi.org/10.1002/ana.20486.
Senel M, Rupprecht TA, Tumani H, et al. The chemokine CXCL13 in acute neuroborreliosis. J Neurol Neurosurg Psychiatry. 2010;81:929–33. https://doi.org/10.1136/jnnp.2009.195438.
DiSano KD, Gilli F, Pachner AR. Intrathecally produced CXCL13: a predictive biomarker in multiple sclerosis. Mult Scler J Exp Transl Clin. 2020;6:2055217320981396. https://doi.org/10.1177/2055217320981396.
Edwards KR, Goyal J, Plavina T, et al. Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis. PLoS ONE. 2013;8:e81007. https://doi.org/10.1371/journal.pone.0081007.
Alvarez E, Piccio L, Mikesell RJ, et al. CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Multiple sclerosis (Houndmills, Basingstoke, England). 2013;19:1204–8. https://doi.org/10.1177/1352458512473362.
Markowicz M, Schotta AM, Kundi M, et al. CXCL13 concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other neurological disorders determined by Luminex and ELISA. Ticks Tick Borne Dis. 2018;9:1137–42. https://doi.org/10.1016/j.ttbdis.2018.04.008.
Ziegler K, Rath A, Schoerner C, et al. Comparative Analysis of the EUROIMMUN CXCL13 ELISA and the ReaScan(R) Lateral Flow Immunoassay for the Diagnosis of Lyme Neuroborreliosis. J Clin Microbiol. 2020. https://doi.org/10.1128/JCM.00207-20.
company) EaP-E. CXCL13 ELISA, https://www.euroimmun.com/documents/Indications/Infections/CSF-diagnostics/EQ_6811_D_UK_A.pdf. 2020.
Krumbholz M, Theil D, Steinmeyer F, et al. CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions. J Neuroimmunol. 2007;190:72–9. https://doi.org/10.1016/j.jneuroim.2007.07.024.
Li M, Ransohoff RM. Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology. Prog Neurobiol. 2008;84:116–31. https://doi.org/10.1016/j.pneurobio.2007.11.003.
Pachner AR, DiSano K, Royce DB, et al. Clinical utility of a molecular signature in inflammatory demyelinating disease. Neurol Neuroimmunol Neuroinflam. 2019;6:e520. https://doi.org/10.1212/nxi.0000000000000520.